Phase II
Recruitment of 39 patients in multicenter European phase 2 trial completed ahead of schedule
Summit Therapeutics plc announced the presentation of new data that explain the link between two key findings in the Company’s Phase 2 clinical trial of ridinilazole for C. difficile infection
Hutchison China MediTech Limited has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase inhibitor, in patients with relapsed or refractory lymphoma.
Target number of clinical sites reached, including leading hospitals and geriatric centers in the US and Europe Patient enrollment expected to complete in mid-2020
It was another busy week for clinical trials. Here’s a look.
Enanta Pharmaceuticals, Inc. announced that new data from its Phase 2a Human Challenge Study of EDP-938 is being presented as a late-breaker oral presentation today at IDWeek™ 2019 in Washington, D.C. EDP-938 is Enanta’s lead N-protein inhibitor being developed for the treatment of RSV infection.
IXALTIS presents positive results from phase 2 studies for its lead compound Litoxetine, a potential “first in class” treatment for urinary incontinence.
A multicenter, international, single-arm, Phase II trial of lurbinectedin in progressive Malignant Pleural Mesothelioma (MPM) has been presented at ESMO.
Evgen Pharma plc announces that the clinical data from the completed open-label Phase II STEM trial was presented in poster format yesterday at the 2019 European Society of Medical Oncology Congress in Barcelona.
NOXXON Pharma N.V. announced the latest clinical results from the Phase 1/2 study of NOX-A12 in combination with Keytruda® in patients with microsatellite-stable, metastatic pancreatic and colorectal cancer in a poster presentation at the European Society for Medical Oncology Congress in Barcelona, Spain.
PRESS RELEASES